Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.
Pharmaceutical
Mon, 05/12/2016 - 07:30
Thu, 17/11/2016 - 15:00
Saffron Walden, UK, 17th November 2016 / Sciad Newswire / Saffron Walden, UK, 17th November 2016 / Sir Simon Campbell, CBE FRS FMedSci, was welcomed b
Thu, 17/11/2016 - 14:30
London, UK, 17th November 2016 / Sciad Newswire / The pharmaceutical industry is a sector of strategic importance, standing on the threshold of innovation, sa
Mon, 31/10/2016 - 09:00
ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory Syncytial Virus (RSV), announced today the initiation of a Phase 1 clinical trial for RV521, its novel orally-active small molecule inhibitor of RSV fusion.
Tue, 27/09/2016 - 09:00
Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from Mercia Technologies PLC.
Wed, 21/09/2016 - 14:00
Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders
Wed, 21/09/2016 - 10:45
Leiden, The Netherlands, and Woburn, MA, 21st September 2016 / Sciad Newswire / Batavia Biosciences received an $8 million grant from the Bill &a
Mon, 12/09/2016 - 09:30
Saffron Walden, UK, 12th September 2016 / Sciad Newswire / Established in 2001, Domainex is a privately-owned, rapidly-growing drug research company with expertis
Mon, 25/07/2016 - 08:00
Prokarium announces funding from UK & Mexican Governments to develop vaccines against Zika, bacterial diarrhoea and Plague.
Wed, 13/07/2016 - 15:00
Cypralis, a life sciences company focussed on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases) has acquired a portfolio of cyclophilin inhibitor assets from SCYNEXIS Inc, a NASDAQ-listed company headquartered in New Jersey, USA.